Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection – PlexAPR™. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance of organ health.
“Transplant rejection can happen at any time after transplantation and requires lifelong management of anti-rejection medications. Same-day delivery of test results is a valuable addition to personalized rejection-risk assessment and improving outcomes”
Also Read: NASA to Provide Update on DART, World’s First Planetary Defense Test
“Transplant rejection can happen at any time after transplantation and requires lifelong management of anti-rejection medications. Same-day delivery of test results is a valuable addition to personalized rejection-risk assessment and improving outcomes,” said Rajeev Sindhi, CEO of Plexision.
PlexAPR™ is based on the presentation of donor antigen by circulating antigen presenting cells, such as B-cells. The test readout is a personalized index, only applicable to the patient being tested. Patient samples will be tested at the company’s CLIA- and CAP-accredited reference laboratory in Pittsburgh.
Roughly 40,000 patients receive solid organ transplants each year in the US. A limited number of drugs are available to prevent organ rejection. Rapid non-invasive surveillance of organ health provided by Plexision can improve survival and quality of life after transplantation.